NCT05168111

Brief Summary

Diquat (DQ), as a conductive biocidal herbicide, is classified as medium according to Chinese pesticide toxicity classification standards. Since the sale and use of paraquat are stopped in 2016, incidents of diquat poisoning have begun to increase. Diquat is very toxic to the human body. Mistake of Diquat can cause damage to multiple organs throughout the body. It has a high fatality rate and no specific treatment.The treatment method has become a research hotspot of modern poisoning treatment. The degree of organ dysfunction caused by DQ poisoning is mainly related to the patient's intake and the distribution of the poison in the human body.So far, the distribution concentration of DQ under the influence of the time gradient in the body and the influence of DQ on the human environment,metabolimics,,immune regulation activity and the comprehensive mechanism of action of various inflammatory factors have not been fully elucidated. Therefore, this research mainly focuses on analyzing the internal environment metabolism research in patients with DQ poisoning, and to conduct exploratory research on the severity of the impact on their organ functions

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 2, 2021

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

December 15, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 23, 2021

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
Last Updated

December 23, 2021

Status Verified

December 1, 2021

Enrollment Period

7 months

First QC Date

December 15, 2021

Last Update Submit

December 22, 2021

Conditions

Keywords

Diquat Metabolomics Toxicology Multicenter

Outcome Measures

Primary Outcomes (1)

  • The poison metabolomics of Diquat

    Improve the correlation between the concentration and metabolism rate of diquat poisoning in vivo and metabolomics and the co-damage color of body organs for bioinformatics analysis and summary

    2022-06

Study Arms (2)

patients of Diquat poisoning

Diagnostic Test: Detect the serum sample

normal persons

Diagnostic Test: Detect the serum sample

Interventions

Detect the serum sample

normal personspatients of Diquat poisoning

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with acute poisoning of diquat are mainly selected.

You may qualify if:

  • Time from poisoning to hospital admission: within 6 hours, 2 The age is greater than 18 years old, less than 65 years old 3 There is at least one target organ dysfunction 4 Previous physical fitness 5 No bad habits (drug use, alcohol addiction)

You may not qualify if:

  • Refuse to join this study
  • Missing/incomplete information
  • Pregnant women, vulnerable groups such as those who have no capacity for civil conduct and cannot determine the consent of their attorneys
  • Chronic organ dysfunction (chronic heart insufficiency, chronic respiratory insufficiency, chronic renal insufficiency, chronic Liver insufficiency)
  • Tumors, blood system diseases, various systemic immune diseases
  • Various infectious diseases (various hepatitis, tuberculosis, AIDS)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

SAHZU

Hanzhou, Zhejiang, 310009, China

RECRUITING

Study Officials

  • Yongan Xu

    SAHZU

    STUDY DIRECTOR

Central Study Contacts

Yongan Xu, Doctor

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 15, 2021

First Posted

December 23, 2021

Study Start

December 2, 2021

Primary Completion

June 30, 2022

Study Completion

June 30, 2022

Last Updated

December 23, 2021

Record last verified: 2021-12

Locations